171 related articles for article (PubMed ID: 26687796)
1. (90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study.
Chevallier P; Eugene T; Robillard N; Isnard F; Nicolini F; Escoffre-Barbe M; Huguet F; Hunault M; Marcais A; Gaschet J; Cherel M; Guillaume T; Delaunay J; Peterlin P; Eveillard M; Thomas X; Ifrah N; Lapusan S; Bodet-Milin C; Barbet J; Faivre-Chauvet A; Ferrer L; Bene MC; Le Houerou C; Goldenberg DM; Wegener WA; Kraeber-Bodéré F
Lancet Haematol; 2015 Mar; 2(3):e108-17. PubMed ID: 26687796
[TBL] [Abstract][Full Text] [Related]
2. Consolidation anti-CD22 fractionated radioimmunotherapy with
Kraeber-Bodere F; Pallardy A; Maisonneuve H; Campion L; Moreau A; Soubeyran I; Le Gouill S; Tournilhac O; Daguindau E; Jardel H; Morineau N; Bouabdallah K; Gyan E; Moles MP; Gressin R; Berthou C; Sadot S; Moreau P; Deau B; Bodet-Milin C; Cazeau AL; Garin E; Salaun PY; Vuillez JP; Gouilleux-Gruart V; Barbet J; Wegener WA; Goldenberg DM; Lamy T; Soubeyran P
Lancet Haematol; 2017 Jan; 4(1):e35-e45. PubMed ID: 27964867
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma.
Witzig TE; Tomblyn MB; Misleh JG; Kio EA; Sharkey RM; Wegener WA; Goldenberg DM
Haematologica; 2014 Nov; 99(11):1738-45. PubMed ID: 25150258
[TBL] [Abstract][Full Text] [Related]
4. BCR-ABL1 molecular remission after 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: proof of principle.
Chevallier P; Bodet-Milin C; Robillard N; Eugene T; Menard A; Le Houerou C; Guillaume T; Delaunay J; Escoffre-Barbe M; Wegener WA; Goldenberg DM; Kraeber-Bodéré F
Eur J Haematol; 2013 Dec; 91(6):552-6. PubMed ID: 23927500
[TBL] [Abstract][Full Text] [Related]
5. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
6. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.
Morschhauser F; Kraeber-Bodéré F; Wegener WA; Harousseau JL; Petillon MO; Huglo D; Trümper LH; Meller J; Pfreundschuh M; Kirsch CM; Naumann R; Kropp J; Horne H; Teoh N; Le Gouill S; Bodet-Milin C; Chatal JF; Goldenberg DM
J Clin Oncol; 2010 Aug; 28(23):3709-16. PubMed ID: 20625137
[TBL] [Abstract][Full Text] [Related]
7. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
Lindén O; Hindorf C; Cavallin-Ståhl E; Wegener WA; Goldenberg DM; Horne H; Ohlsson T; Stenberg L; Strand SE; Tennvall J
Clin Cancer Res; 2005 Jul; 11(14):5215-22. PubMed ID: 16033839
[TBL] [Abstract][Full Text] [Related]
8. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study.
Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X
Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088
[TBL] [Abstract][Full Text] [Related]
9. Final results of a phase I radioimmunotherapy trial using (186)Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma.
Postema EJ; Raemaekers JM; Oyen WJ; Boerman OC; Mandigers CM; Goldenberg DM; van Dongen GA; Corstens FH
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3995S-4002S. PubMed ID: 14506199
[TBL] [Abstract][Full Text] [Related]
10. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.
Raetz EA; Cairo MS; Borowitz MJ; Blaney SM; Krailo MD; Leil TA; Reid JM; Goldenberg DM; Wegener WA; Carroll WL; Adamson PC;
J Clin Oncol; 2008 Aug; 26(22):3756-62. PubMed ID: 18669463
[TBL] [Abstract][Full Text] [Related]
11. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
Benjamin R; Jain N; Maus MV; Boissel N; Graham C; Jozwik A; Yallop D; Konopleva M; Frigault MJ; Teshima T; Kato K; Boucaud F; Balandraud S; Gianella-Borradori A; Binlich F; Marchiq I; Dupouy S; Almena-Carrasco M; Pannaux M; Fouliard S; Brissot E; Mohty M;
Lancet Haematol; 2022 Nov; 9(11):e833-e843. PubMed ID: 36228643
[TBL] [Abstract][Full Text] [Related]
12. Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study.
Chevallier P; Huguet F; Raffoux E; Etienne A; Leguay T; Isnard F; Robillard N; Guillaume T; Delaunay J; Charbonnier A; Pigneux A; Peterlin P; Bené MC; Wegener WA; Goldenberg DM; Dombret H
Haematologica; 2015 Apr; 100(4):e128-31. PubMed ID: 25552705
[No Abstract] [Full Text] [Related]
13. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.
Kantarjian HM; DeAngelo DJ; Advani AS; Stelljes M; Kebriaei P; Cassaday RD; Merchant AA; Fujishima N; Uchida T; Calbacho M; Ejduk AA; O'Brien SM; Jabbour EJ; Zhang H; Sleight BJ; Vandendries ER; Marks DI
Lancet Haematol; 2017 Aug; 4(8):e387-e398. PubMed ID: 28687420
[TBL] [Abstract][Full Text] [Related]
14. Targeting CD22 in B-cell malignancies: current status and clinical outlook.
Sullivan-Chang L; O'Donnell RT; Tuscano JM
BioDrugs; 2013 Aug; 27(4):293-304. PubMed ID: 23696252
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.
Schindler J; Gajavelli S; Ravandi F; Shen Y; Parekh S; Braunchweig I; Barta S; Ghetie V; Vitetta E; Verma A
Br J Haematol; 2011 Aug; 154(4):471-6. PubMed ID: 21732928
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
Issa JJ; Roboz G; Rizzieri D; Jabbour E; Stock W; O'Connell C; Yee K; Tibes R; Griffiths EA; Walsh K; Daver N; Chung W; Naim S; Taverna P; Oganesian A; Hao Y; Lowder JN; Azab M; Kantarjian H
Lancet Oncol; 2015 Sep; 16(9):1099-1110. PubMed ID: 26296954
[TBL] [Abstract][Full Text] [Related]
17. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
[TBL] [Abstract][Full Text] [Related]
18. Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial.
Ocean AJ; Pennington KL; Guarino MJ; Sheikh A; Bekaii-Saab T; Serafini AN; Lee D; Sung MW; Gulec SA; Goldsmith SJ; Manzone T; Holt M; O'Neil BH; Hall N; Montero AJ; Kauh J; Gold DV; Horne H; Wegener WA; Goldenberg DM
Cancer; 2012 Nov; 118(22):5497-506. PubMed ID: 22569804
[TBL] [Abstract][Full Text] [Related]
19. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
[TBL] [Abstract][Full Text] [Related]
20. Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma.
Ogura M; Tobinai K; Hatake K; Davies A; Crump M; Ananthakrishnan R; Ishibashi T; Paccagnella ML; Boni J; Vandendries E; MacDonald D
Clin Cancer Res; 2016 Oct; 22(19):4807-4816. PubMed ID: 27154915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
